Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and

Provides Corporate Update

•
CRB-701 Phase 1 trial in China is ahead of schedule with dose escalation completion expected Q4 2023 and U.S. clinical trial start planned for Q1 2024
•
Preliminary clinical PK data indicates CRB-701 has a longer half-life and reduced levels of circulating free MMAE relative to published data for PADCEV®
•
CRB-601 IND submission is on track for Q4 2023

 

Norwood, MA, August 8, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today provided a corporate update and reported financial results for the second quarter of 2023.

 

“During the second quarter, substantial progress was made advancing CRB-701, our next generation Nectin-4 antibody drug conjugate (ADC), in-licensed earlier this year from CSPC Pharmaceutical Group (CSPC)” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Following a recent visit to CSPC in China, we’re pleased to share that the Phase 1 dose escalation in patients with Nectin-4 enriched solid tumors is proceeding well and is currently ahead of the planned schedule. We now anticipate that the dose escalation portion of this trial in China will be completed in Q4 2023. Accordingly, we are accelerating our own development plans for CRB-701, and now anticipate initiating our U.S. clinical trial in Q1 2024 under the currently active US IND. Preliminary clinical data generated to date demonstrates a differentiated pharmacokinetic profile relative to other Nectin-4 targeting agents.”

 

“Development of our anti-aVb8 mAb CRB-601, is also ongoing and we were pleased to present the latest pre-clinical data for this asset at the AACR 2023 annual meeting in April,” continued Dr. Cohen. “The data that was presented builds upon the robust target engagement previously presented alone and in combination with anti-PD-1. We believe this data reinforces the potential of this new approach in blocking activation of TGFβ locally in the TME. We plan to submit our Investigational New Drug (IND) application for CRB-601 in Q4 2023 and anticipate initiating our Phase 1 clinical trial in the first half of 2024. We note that key competitive programs from Pfizer and AbbVie have progressed to Phase 2 clinical trials, and we see this as supportive evidence that this class of drugs warrant further clinical exploration. It will be a busy 12 months for us, as we continue our evolution into a precision oncology company, and advance both of our programs into the clinic in the US.”

 

Key Corporate and Program Updates:

•
CRB-701 next generation Nectin-4 ADC:

 

o
The dose exploration of CRB-701 in Nectin-4 positive solid tumors is ahead of schedule. CSPC, our development partner, is enrolling its Phase 1 dose escalation study in China and Corbus now estimates this escalation will be completed by the end of 2023 and plans to initiate an abbreviated Phase 1 in the US in the first quarter of 2024 leveraging the clinical experience from China.

 

o
Preliminary clinical pharmacology data indicates CRB-701 is differentiated from PADCEV® with an increased half-life and reduced levels of circulating free monomethyl auristatin E (MMAE).
o
Corbus licensed CRB-701 from CSPC in February 2023 and has exclusive development and commercialization rights in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia.
o
Nectin-4 is a clinically validated tumor associated antigen in urothelial cancer. The Nectin-4 ADC PADCEV® (SeaGen/Astellas) is approved for use in late metastatic urothelial cancer and recently received an expanded label from the Food and Drug Administration based on accelerated approval for use in combination with KEYTRUDA® for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.
o
CRB-701 is designed to achieve an improved therapeutic index and will be explored in urothelial cancer, as well as a range of other Nectin-4 expressing solid tumors.
o
CRB-701 has key features that support a differentiated profile including a novel Nectin-4 antibody and a site-specific conjugation linker that results in faster ADC internalization, longer half-life, and reduced payload release in plasma. Pre-clinical and dose escalation data demonstrates the potential to achieve higher exposures with CRB-701 resulting in an opportunity to improve the therapeutic index.
•
CRB-601 blocking the activation of TGFβ
o
CRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody (mAb) designed to block the activation of latent TGFβ within the tumor micro-environment (TME). CRB-601 significantly inhibits tumor growth as a monotherapy in murine models and enhances the efficacy of anti-PD-1 immunotherapy as a combination in checkpoint inhibitor (CPI) sensitive and CPI-resistant tumor models.
o
Corbus presented pre-clinical data at the American Association of Cancer Research (AACR) 2023 annual meeting indicating that CRB-601 exhibited dose dependent tumor growth inhibition (TGI) in the EMT6 tumor model which was significantly augmented in combination with anti-PD-1 therapy. These effects were associated with changes in TME immune cell populations with marked increases in infiltrating T cells, NK cells and M1 polarized macrophages. Efficacy correlated with cell surface αvβ8 occupancy by CRB-601. CRB-601 treatment downregulated phosphorylation of SMAD proteins, pSMAD2 and pSMAD3, consistent with blockade of the TGFβ signaling pathway.
o
The IND submission for CRB-601 is anticipated in Q4 2023, and the Company expects to enroll the first patient in its Phase 1 study in the first half of 2024.
o
We note that recent events from other development programs of mAb with a similar mechanism of action including those of Pfizer and AbbVie indicate their advancement into Phase 2 clinical trials.

 

Financial Results for Quarter Ended June 30, 2023:

The Company reported a net loss of approximately $8.8 million, or a net loss per diluted share of $2.05, for the three months ended June 30, 2023, compared to a net loss of approximately $13.2 million, or a net loss per diluted share of $3.18, for the same period in 2022.

Operating expenses decreased by $4.1 million to approximately $8.2 million for the three months ended June 30, 2023, compared to $12.3 million in the comparable period in the prior year. The decrease was primarily attributable to a litigation settlement payment of $5.0 million in 2022 and reduction in general and administrative expenses in the current period offset by increases in product development expenses for CRB-701 and CRB-601.

As of June 30, 2023, the company has $36.6 million of cash, cash equivalents and investments on hand which is expected to fund operations through the second quarter of 2024, based on the current planned expenditures.

 

About Corbus

 

Corbus Pharmaceuticals Holdings, Inc. (the “Company” or “Corbus”) is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.

Forward-Looking Statements


This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

INVESTOR CONTACT:

Sean Moran

Chief Financial Officer

Corbus Pharmaceuticals

smoran@corbuspharma.com

 

Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

---tables to follow---

 

 

Corbus Pharmaceuticals Holdings, Inc.

Condensed Consolidated Balance Sheets (Unaudited)

 

 

 

June 30, 2023

 

 

December 31, 2022

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

8,349,346

 

 

$

17,002,715

 

Investments

 

 

28,216,560

 

 

 

42,194,296

 

Restricted cash

 

 

192,475

 

 

 

192,475

 

Prepaid expenses and other current assets

 

 

1,515,616

 

 

 

791,616

 

Total current assets

 

 

38,273,997

 

 

 

60,181,102

 

Restricted cash

 

 

477,425

 

 

 

477,425

 

Property and equipment, net

 

 

1,273,602

 

 

 

1,613,815

 

Operating lease right of use assets

 

 

3,486,416

 

 

 

3,884,252

 

Other assets

 

 

211,943

 

 

 

155,346

 

Total assets

 

$

43,723,383

 

 

$

66,311,940

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Notes payable

 

$

51,157

 

 

$

353,323

 

Accounts payable

 

 

1,505,734

 

 

 

2,173,963

 

Accrued expenses

 

 

6,418,803

 

 

 

5,999,252

 

Derivative liability

 

 

36,868

 

 

 

36,868

 

Operating lease liabilities, current

 

 

1,357,240

 

 

 

1,280,863

 

Current portion of long-term debt

 

 

7,016,096

 

 

 

2,795,669

 

Total current liabilities

 

 

16,385,898

 

 

 

12,639,938

 

Long-term debt, net of debt discount

 

 

11,319,365

 

 

 

15,984,426

 

License agreement payable, noncurrent

 

 

2,500,000

 

 

 

—

 

Other long-term liabilities

 

 

22,205

 

 

 

22,205

 

Operating lease liabilities, noncurrent

 

 

3,975,329

 

 

 

4,675,354

 

Total liabilities

 

 

34,202,797

 

 

 

33,321,923

 

Stockholders’ equity

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2023 and December 31, 2022

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value; 300,000,000 shares authorized,
  4,422,741 and 4,171,297 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively

 

 

442

 

 

 

417

 

Additional paid-in capital

 

 

428,153,252

 

 

 

425,196,359

 

Accumulated deficit

 

 

(418,609,320

)

 

 

(392,080,667

)

Accumulated other comprehensive loss

 

 

(23,788

)

 

 

(126,092

)

Total stockholders’ equity

 

 

9,520,586

 

 

 

32,990,017

 

Total liabilities and stockholders’ equity

 

$

43,723,383

 

 

$

66,311,940

 

 

Corbus Pharmaceuticals Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

 

 

 

For the Three Months
Ended June 30,

 

 

For the Six Months
Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

4,248,705

 

 

$

2,499,642

 

 

$

17,637,048

 

 

$

5,785,878

 

General and administrative

 

 

3,940,286

 

 

 

4,840,368

 

 

 

7,848,968

 

 

 

10,071,291

 

Litigation Settlement

 

 

—

 

 

 

5,000,000

 

 

 

—

 

 

 

5,000,000

 

Total operating expenses

 

 

8,188,991

 

 

 

12,340,010

 

 

 

25,486,016

 

 

 

20,857,169

 

Operating loss

 

 

(8,188,991

)

 

 

(12,340,010

)

 

 

(25,486,016

)

 

 

(20,857,169

)

Other expense, net:

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense), net

 

 

182,657

 

 

 

(208,683

)

 

 

412,164

 

 

 

(402,034

)

Interest expense, net

 

 

(775,586

)

 

 

(490,339

)

 

 

(1,453,608

)

 

 

(949,248

)

Foreign currency exchange loss, net

 

 

(1,921

)

 

 

(209,856

)

 

 

(1,193

)

 

 

(477,679

)

Other expense, net

 

 

(594,850

)

 

 

(908,878

)

 

 

(1,042,637

)

 

 

(1,828,961

)

Net loss

 

$

(8,783,841

)

 

$

(13,248,888

)

 

$

(26,528,653

)

 

$

(22,686,130

)

Net loss per share, basic and diluted

 

$

(2.05

)

 

$

(3.18

)

 

$

(6.27

)

 

$

(5.44

)

Weighted average number of common shares outstanding, basic and diluted

 

 

4,277,701

 

 

 

4,170,464

 

 

 

4,229,894

 

 

 

4,170,255

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(8,783,841

)

 

$

(13,248,888

)

 

$

(26,528,653

)

 

$

(22,686,130

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Change in unrealized gain (loss) on marketable debt securities

 

 

44,681

 

 

 

50,373

 

 

 

102,304

 

 

 

(56,875

)

Total other comprehensive income (loss)

 

 

44,681

 

 

 

50,373

 

 

 

102,304

 

 

 

(56,875

)

Total comprehensive loss

 

$

(8,739,160

)

 

$

(13,198,515

)

 

$

(26,426,349

)

 

$

(22,743,005

)